CDK4/6 inhibitors in advanced breast cancer, what is beyond?

Main Article Content

Amrallah A. Mohammed *
Hanaa Rashied
Fifi Mostafa Elsayed
(*) Corresponding Author:
Amrallah A. Mohammed |


Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.

Downloads month by month


Download data is not yet available.

Article Details